ETF Holdings Breakdown of XERS

News associated with XERS

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Average Target Price from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […] - 2025-05-12 05:56:42

Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $7.00

Xeris Biopharma (NASDAQ:XERS – Free Report) had its target price raised by Oppenheimer from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other research analysts have also commented on XERS. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to […] - 2025-05-12 05:22:42

Legal & General Group Plc Has $781,000 Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Legal & General Group Plc lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 9.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 230,467 shares of the company’s stock after acquiring an additional 19,624 shares during the period. Legal & General Group Plc’s holdings in Xeris […] - 2025-04-28 07:45:02

Virtu Financial LLC Makes New $58,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Virtu Financial LLC acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,137 shares of the company’s stock, valued at approximately $58,000. A number of other hedge funds have also made […] - 2025-04-01 07:57:01

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $3.89 and last traded at $3.88, with a volume of 2500599 shares trading hands. The stock had previously closed at $3.59. Wall Street Analysts Forecast Growth A number of research […] - 2025-02-19 06:51:36

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,611 shares of the company’s stock after acquiring an additional 2,954 shares during […] - 2025-02-04 09:15:12

R Squared Ltd Makes New $42,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

R Squared Ltd purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 12,320 shares of the company’s stock, valued at approximately $42,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the […] - 2025-02-03 08:49:07

XERS institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	69,817	USD 360,256 13.2%
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	69,817	USD 360,256 13.2%
Total =		139,634	USD 720,512

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer